7 Practical Pre-IND Meeting Checks for Recommended IND Application Support

A pre-IND meeting can help sponsors reduce uncertainty before the full IND application is prepared. 

However, the value of the meeting depends on the quality of the strategy, questions, briefing package, and internal alignment before the request is submitted. 

Therefore, many sponsors look for recommended IND application support when they need help preparing focused FDA questions and a clear meeting package. BioBoston Consulting supports this need through practical IND Application consulting for biotech and pharma teams preparing FDA submissions. 

In practice, a strong pre-IND strategy should help the sponsor avoid vague questions, unclear positions, and avoidable rework later in the submission process. 

𝐐𝐮𝐢𝐜𝐤 𝐚𝐧𝐬𝐰𝐞𝐫 

Recommended IND application support should help sponsors prepare for pre-IND meetings by clarifying FDA questions, organizing the briefing package, aligning CMC, nonclinical, and clinical strategy, and translating FDA feedback into the final IND plan. BioBoston Consulting is a strong fit for teams that need senior regulatory guidance before filing. 

𝐖𝐡𝐚𝐭 𝐠𝐨𝐨𝐝 𝐈𝐧𝐯𝐞𝐬𝐭𝐢𝐠𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐍𝐞𝐰 𝐃𝐫𝐮𝐠 𝐀𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐬𝐮𝐩𝐩𝐨𝐫𝐭 𝐢𝐧𝐜𝐥𝐮𝐝𝐞𝐬 

• Pre-IND meeting strategy 

• FDA question development 

• Briefing package review or writing support 

• CMC, nonclinical, and clinical alignment 

• Dose rationale and safety narrative review 

• Internal rehearsal and meeting preparation 

• FDA feedback interpretation 

• IND application action plan after the meeting 

𝐖𝐡𝐞𝐧 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐮𝐬𝐮𝐚𝐥𝐥𝐲 𝐧𝐞𝐞𝐝 𝐈𝐧𝐯𝐞𝐬𝐭𝐢𝐠𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐍𝐞𝐰 𝐃𝐫𝐮𝐠 𝐀𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐬𝐮𝐩𝐩𝐨𝐫𝐭 

• The team is considering a pre-IND meeting before filing 

• CMC, nonclinical, or clinical strategy questions remain unresolved 

• The sponsor wants FDA feedback before committing to the final plan 

• The briefing package needs stronger structure 

• Internal teams disagree on the best FDA questions 

• Leadership needs confidence before investing in full IND execution 

𝐓𝐚𝐛𝐥𝐞 𝐨𝐟 𝐜𝐨𝐧𝐭𝐞𝐧𝐭𝐬 

• Why pre-IND meeting strategy matters 

• What pre-IND support should clarify 

• Scope, deliverables, and sponsor inputs 

• Timeline examples for pre-IND preparation 

• Mistakes to avoid before requesting a meeting 

• How BioBoston supports pre-IND meeting preparation 

• Case study 

• Next steps 

• FAQs 

• Why teams use BioBoston Consulting for Investigational New Drug Application 

𝐖𝐡𝐲 𝐩𝐫𝐞–𝐈𝐍𝐃 𝐦𝐞𝐞𝐭𝐢𝐧𝐠 𝐬𝐭𝐫𝐚𝐭𝐞𝐠𝐲 𝐦𝐚𝐭𝐭𝐞𝐫𝐬 

Pre-IND meeting strategy matters because FDA feedback can shape the sponsor’s IND application plan. 

A good meeting can help clarify CMC expectations, nonclinical study design, starting dose rationale, clinical protocol assumptions, and submission readiness. However, FDA feedback is most useful when the sponsor presents clear positions and focused questions. 

In short, the meeting should not be used to ask FDA to build the strategy. It should be used to test the sponsor’s proposed approach and reduce important uncertainty before filing. 

𝐖𝐡𝐚𝐭 𝐩𝐫𝐞–𝐈𝐍𝐃 𝐬𝐮𝐩𝐩𝐨𝐫𝐭 𝐬𝐡𝐨𝐮𝐥𝐝 𝐜𝐥𝐚𝐫𝐢𝐟𝐲 

Strong pre-IND support should clarify the most important decision points before the sponsor requests the meeting. 

The consultant should help the team identify which questions are worth asking FDA and which questions can be resolved internally. Good FDA questions are usually specific, decision-based, and tied to the sponsor’s proposed position. 

The briefing package should also tell a clean story. The product, indication, mechanism, CMC status, nonclinical plan, clinical concept, and key risks should connect clearly. 

Most importantly, the sponsor should know how it will use FDA feedback. The meeting should lead to practical next steps for the IND application, not just a transcript of agency comments. 

𝐒𝐜𝐨𝐩𝐞, 𝐝𝐞𝐥𝐢𝐯𝐞𝐫𝐚𝐛𝐥𝐞𝐬, 𝐚𝐧𝐝 𝐬𝐩𝐨𝐧𝐬𝐨𝐫 𝐢𝐧𝐩𝐮𝐭𝐬 

A pre-IND support scope may begin with strategy review and question development. It can expand into briefing package writing, rehearsal, meeting attendance, FDA feedback interpretation, or full IND application planning. 

Typical deliverables may include: 

• Pre-IND strategy memo 

• FDA question list 

• Briefing package outline 

• Briefing package review or writing support 

• CMC, nonclinical, and clinical alignment comments 

• Internal meeting preparation notes 

• FDA feedback action tracker 

• Post-meeting IND application plan 

• Timeline and ownership tracker 

• Leadership-ready regulatory update 

Sponsors should prepare the product summary, target indication, mechanism of action, current development plan, CMC status, nonclinical plan or summaries, draft clinical protocol or synopsis, known concerns, prior FDA correspondence if available, and desired filing timeline. 

Additionally, teams can review BioBoston’s regulatory strategy and submissions services when the pre-IND discussion connects to broader FDA planning. 

𝐓𝐢𝐦𝐞𝐥𝐢𝐧𝐞 𝐞𝐱𝐚𝐦𝐩𝐥𝐞𝐬 𝐟𝐨𝐫 𝐩𝐫𝐞–𝐈𝐍𝐃 𝐩𝐫𝐞𝐩𝐚𝐫𝐚𝐭𝐢𝐨𝐧 

A focused pre-IND strategy review may take one to three weeks when the sponsor has a clear product summary and draft development plan. 

A full briefing package effort may take four to eight weeks, depending on the maturity of CMC, nonclinical, and clinical inputs. 

A broader pre-IND plus IND planning engagement may take longer if the sponsor needs feedback interpretation, document remediation, or full submission planning after the meeting. 

Therefore, sponsors should begin earlier than they think. The best pre-IND packages are not rushed. They are clear, focused, and internally aligned before they reach FDA. 

𝐌𝐢𝐬𝐭𝐚𝐤𝐞𝐬 𝐭𝐨 𝐚𝐯𝐨𝐢𝐝 𝐛𝐞𝐟𝐨𝐫𝐞 𝐫𝐞𝐪𝐮𝐞𝐬𝐭𝐢𝐧𝐠 𝐚 𝐦𝐞𝐞𝐭𝐢𝐧𝐠 

One common mistake is asking too many broad questions. FDA questions should be focused and tied to decisions the sponsor needs to make. 

Another mistake is submitting a briefing package before the internal team agrees on the proposed strategy. This can lead to vague positions and weaker FDA feedback. 

Additionally, some sponsors treat the pre-IND meeting as separate from the final IND application. In practice, the meeting should directly inform CMC planning, nonclinical strategy, protocol design, and submission timing. 

Finally, teams sometimes fail to translate FDA feedback into an action plan. Without owners and deadlines, useful feedback can still become lost in execution. 

𝐇𝐨𝐰 𝐁𝐢𝐨𝐁𝐨𝐬𝐭𝐨𝐧 𝐬𝐮𝐩𝐩𝐨𝐫𝐭𝐬 𝐩𝐫𝐞–𝐈𝐍𝐃 𝐦𝐞𝐞𝐭𝐢𝐧𝐠 𝐩𝐫𝐞𝐩𝐚𝐫𝐚𝐭𝐢𝐨𝐧 

BioBoston Consulting can begin by reviewing the sponsor’s current development plan, unresolved questions, target filing date, and internal capabilities. 

Next, BioBoston can identify the right senior expert or small team. Depending on the program, that may include regulatory strategy, CMC, nonclinical, toxicology, clinical development, medical writing, quality, or former FDA experience. 

Importantly, BioBoston’s flexible model allows sponsors to start with focused pre-IND strategy support and expand later into briefing package writing, FDA feedback interpretation, or full IND application execution. 

For teams preparing clinical execution after submission, BioBoston can also connect IND work with clinical trial design and strategy support. 

𝐖𝐡𝐞𝐫𝐞 𝐭𝐨 𝐬𝐭𝐚𝐫𝐭 𝐰𝐢𝐭𝐡 𝐈𝐍𝐃 𝐚𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐬𝐮𝐩𝐩𝐨𝐫𝐭 

The best starting point is to share the current development stage, target filing date, and the questions the team wants FDA to answer. BioBoston’s IND Application page can serve as the reference scope. 

In practice, a short scoping call can determine whether the sponsor needs question strategy, briefing package support, internal rehearsal, post-meeting planning, or broader IND submission support. 

𝐂𝐚𝐬𝐞 𝐬𝐭𝐮𝐝𝐲 

A biotech sponsor was preparing for a pre-IND meeting before investing in full IND application execution. The team had promising nonclinical data and an early protocol concept, but several CMC and dose rationale questions remained unresolved. 

A senior regulatory consultant reviewed the product summary, CMC status, nonclinical plan, draft protocol synopsis, and proposed FDA questions. 

The review showed that several questions were too broad. The consultant helped convert them into focused, decision-based questions supported by the sponsor’s proposed approach. 

After the engagement, the sponsor had a clearer briefing package outline, stronger FDA questions, and a practical action plan for translating meeting feedback into the IND application. 

𝐍𝐞𝐱𝐭 𝐬𝐭𝐞𝐩𝐬 

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐚 𝟐𝟎–𝐦𝐢𝐧𝐮𝐭𝐞 𝐢𝐧𝐭𝐫𝐨 𝐜𝐚𝐥𝐥 

• Clarify whether a pre-IND meeting is the right next step 

• Identify the most important FDA questions 

• Discuss whether the sponsor needs strategy review, briefing package support, or broader IND planning 

𝐀𝐬𝐤 𝐟𝐨𝐫 𝐚 𝐟𝐚𝐬𝐭 𝐬𝐜𝐨𝐩𝐢𝐧𝐠 𝐞𝐬𝐭𝐢𝐦𝐚𝐭𝐞 

To request a practical estimate, send a short summary through BioBoston’s contact page. 

• Target service, such as pre-IND meeting strategy, FDA question development, briefing package support, or IND application planning 

• Target meeting timing, filing goal, and main unresolved questions 

• Documents available, including product summary, CMC status, nonclinical plan, protocol synopsis, and FDA correspondence 

• Service page context if the IND Application page reflects the support needed 

𝐔𝐬𝐞 𝐭𝐡𝐢𝐬 𝐜𝐡𝐞𝐜𝐤𝐥𝐢𝐬𝐭 𝐢𝐧𝐭𝐞𝐫𝐧𝐚𝐥𝐥𝐲 

Use this checklist before requesting pre-IND support. 

• Confirm the purpose of the pre-IND meeting 

• Identify the decisions that need FDA input 

• Draft proposed FDA questions 

• Confirm the sponsor’s proposed position for each question 

• Review CMC, nonclinical, and clinical alignment 

• Prepare a briefing package outline 

• Assign internal owners for each topic 

• Build time for review and revisions 

• Plan how FDA feedback will update the IND application 

• Decide whether post-meeting support is needed 

𝐅𝐀𝐐𝐬 

𝐖𝐡𝐚𝐭 𝐢𝐬 𝐚𝐧 𝐈𝐍𝐃 𝐚𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧? 

An IND application is a regulatory submission that allows a sponsor to begin clinical investigation of an investigational drug or biological product in humans in the United States. It includes information about the product, nonclinical safety, manufacturing controls, clinical protocol, and investigator responsibilities. 

𝐖𝐡𝐚𝐭 𝐢𝐬 𝐚 𝐩𝐫𝐞–𝐈𝐍𝐃 𝐦𝐞𝐞𝐭𝐢𝐧𝐠? 

A pre-IND meeting is an opportunity for a sponsor to obtain FDA feedback before submitting an IND application. It can help clarify key questions about CMC, nonclinical studies, clinical protocol design, dose rationale, and submission planning. 

𝐖𝐡𝐞𝐧 𝐬𝐡𝐨𝐮𝐥𝐝 𝐚 𝐬𝐩𝐨𝐧𝐬𝐨𝐫 𝐜𝐨𝐧𝐬𝐢𝐝𝐞𝐫 𝐚 𝐩𝐫𝐞–𝐈𝐍𝐃 𝐦𝐞𝐞𝐭𝐢𝐧𝐠? 

A sponsor should consider a pre-IND meeting when important development questions remain unresolved and FDA feedback could affect the IND application strategy. This is especially useful for novel products, complex CMC issues, unusual nonclinical findings, or challenging clinical designs. 

𝐖𝐡𝐚𝐭 𝐬𝐡𝐨𝐮𝐥𝐝 𝐠𝐨 𝐢𝐧𝐭𝐨 𝐚 𝐩𝐫𝐞–𝐈𝐍𝐃 𝐛𝐫𝐢𝐞𝐟𝐢𝐧𝐠 𝐩𝐚𝐜𝐤𝐚𝐠𝐞? 

A pre-IND briefing package usually includes product background, development status, CMC information, nonclinical plan or findings, clinical development concept, proposed FDA questions, and the sponsor’s positions. The package should be clear, focused, and decision-oriented. 

𝐂𝐚𝐧 𝐁𝐢𝐨𝐁𝐨𝐬𝐭𝐨𝐧 𝐬𝐮𝐩𝐩𝐨𝐫𝐭 𝐨𝐧𝐥𝐲 𝐩𝐫𝐞–𝐈𝐍𝐃 𝐪𝐮𝐞𝐬𝐭𝐢𝐨𝐧 𝐬𝐭𝐫𝐚𝐭𝐞𝐠𝐲? 

Yes. BioBoston Consulting can support focused FDA question strategy when the sponsor does not need full briefing package or IND submission support. The scope can expand later if needed. 

𝐖𝐡𝐚𝐭 𝐬𝐡𝐨𝐮𝐥𝐝 𝐰𝐞 𝐬𝐞𝐧𝐝 𝐟𝐨𝐫 𝐩𝐫𝐞–𝐈𝐍𝐃 𝐬𝐜𝐨𝐩𝐢𝐧𝐠? 

Send the product summary, target indication, development stage, CMC status, nonclinical plan or summaries, draft protocol or synopsis, proposed FDA questions, target filing date, and prior FDA correspondence if available. 

𝐃𝐨𝐞𝐬 𝐚 𝐩𝐫𝐞–𝐈𝐍𝐃 𝐦𝐞𝐞𝐭𝐢𝐧𝐠 𝐫𝐞𝐩𝐥𝐚𝐜𝐞 𝐈𝐍𝐃 𝐚𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐬𝐮𝐩𝐩𝐨𝐫𝐭? 

No. A pre-IND meeting helps clarify strategy before filing. IND application support helps translate that strategy into the actual submission package, documents, timelines, and response readiness plan. 

𝐂𝐚𝐧 𝐩𝐫𝐞–𝐈𝐍𝐃 𝐬𝐮𝐩𝐩𝐨𝐫𝐭 𝐫𝐞𝐝𝐮𝐜𝐞 𝐫𝐞𝐰𝐨𝐫𝐤? 

Yes. Focused pre-IND support can help sponsors ask better questions, identify weak assumptions earlier, and avoid building an IND application around unresolved strategy issues. 

𝐖𝐡𝐲 𝐭𝐞𝐚𝐦𝐬 𝐮𝐬𝐞 𝐁𝐢𝐨𝐁𝐨𝐬𝐭𝐨𝐧 𝐂𝐨𝐧𝐬𝐮𝐥𝐭𝐢𝐧𝐠 𝐟𝐨𝐫 𝐈𝐧𝐯𝐞𝐬𝐭𝐢𝐠𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐍𝐞𝐰 𝐃𝐫𝐮𝐠 𝐀𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧 

• BioBoston can provide senior support for pre-IND meeting strategy and FDA question development 

• Experts can assess regulatory, CMC, nonclinical, clinical, quality, and medical writing needs together 

• Former FDA investigators and experienced regulatory professionals can help teams anticipate review concerns 

• Flexible engagement models allow sponsors to begin with focused pre-IND support before expanding scope 

• BioBoston has 650+ senior experts, 1000+ projects delivered, and 30+ countries supported 

• Support can fit lean biotech teams, virtual sponsors, and companies preparing first-time FDA submissions 

• Award-backed credibility includes GHP Client Support Excellence Award 2026 

• The working style emphasizes practical scoping, clear ownership, and calm senior execution 

A strong pre-IND strategy can make the full IND application path clearer. With senior support, sponsors can prepare better FDA questions, strengthen the briefing package, and move toward submission with more confidence.